S
Spero Therapeutics
Multi-Asset, clinical-stage biopharmaceutical company focused on multidrug-resistant bacterial infections
At a glance
- Status
- Listed
- Founded
- 2013
- Headquarters
- Cambridge, United States
- Listing
- IPO 2017
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
- ACAtlas Peak Capital
Atlas Venture
Series A5 investors entered at this stage
- PFPartners Innovation Fund
- LVLundbeckfonden Ventures
- SOSR One
- TGThe Kraft Group
- LULundbeckfonden
Series B and later6 investors entered at this stage
- MHMassachusetts General Hospital
- RCRock Springs Capital
- OPOsage University Partners
GV
RA Capital Management- HSHarvard Medical School
Source: Dealroom Talent Intelligence.
Alumni founders
Former Spero Therapeutics employees who went on to found companies, sorted by Dealroom signal score.
LBLaguna BioEst. 2022
Jonathan KotulaUnited States
SMStylus MedicineEst. 2022
Joshua ResnickUnited States
SYSynlogicEst. 2014
Ankit MahadeviaUnited States
STSanti TherapeuticsEst. 2019
Milind Deshpande, PhD.United StatesGlobal footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Spero Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Spero Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.